Skip to main content

Table 3 Summary of cardiovascular irAEs

From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

Case Cardiovascular complications Age (years), sex Malignancy ICI Days from first ICI administration to cardiovascular irAEs Days from non-cardiovascular irAEs to cardiovascular irAEs Management Outcome
1 Paf 66, M Renal cancer Nivolumab 64 15 Pilsicainide Survived
2 Paf 71, M NSCLC Pembrolizumab 35 25 Anticoagulant therapy Survived
3 AFL 44, F NSCLC Nivolumab 4 (-) Bisoprolol Cancer death
4 PSVT 72, F NSCLC Nivolumab 89 65 Bisoprolol Cancer death
5 VT 71, M Melanoma Pembrolizumab 6 (-) Catheter ablation Survived
6 AP 74, M NSCLC Nivolumab 201 (-) PCI Survived
7 AP 79, M NSCLC Nivolumab 1102 986 Nitrous acid Survived
8 VSP 58, M Melanoma Pembrolizumab 294 204 Nitrous acid Survived
9 Pericardial effusion 45, M NSCLC Pembrolizumab 59 58 Pericardial drainage Cancer death
10 Pericardial effusion 45, M NSCLC Pembrolizumab 253 246 Pericardial drainage Cancer death
11 PE 77, F NSCLC Pembrolizumab 161 (-) Anticoagulant therapy Survived
12 HF 71, M NSCLC Nivolumab 72 (-) Diuretics Cancer death
13 Fulminant myocarditis 59, M Melanoma Ipilimumab
 → 
Nivolumab
495 418 MCS + PSL pulse Survived from myocarditis, Cancer death
14 Myocardial vasculitis 79, F Melanoma Pembrolizumab 263 74 PSL Survived
  1. ICI immune checkpoint inhibitor, Paf paroxysmal atrial fibrillation, AFL atrial flutter, PSVT paroxysmal supraventricular tachycardia, VT ventricular tachycardia, AP angina pectoris, VSP vasospastic angina, PE pulmonary embolism, HF heart failure, NSCLC non-small cell lung cancer, PCI percutaneous coronary intervention, MCS mechanical circulatory support, PSL prednisolone, Other abbreviations as in Table 1